SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

On Tuesday, H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock.

PNC Financial Services Group Inc. raised its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 22.9% during ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect ORIC Pharmaceuticals to ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include ...

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include ...

Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase ...